Penwest plans new staff cuts

Penwest Pharmaceuticals reported record second quarter revenue but said it plans new staff cuts in order to build profitability. The company is sharpening its axe to attack "non-drug delivery partnership-funded cash expenses...We expect to achieve these expense reductions by the fourth quarter of this year through a further reduction in staff levels as well as an overall reduction in other costs." Penwest release

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.